文献速递妇科

症状指数联合第二代多变量生物标志物检测预测附件包块患者卵巢癌

Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
PubMed 文献 · Gynecol Oncol · 2018-06-19

前瞻性研究纳入218例因附件包块拟手术患者,评估症状指数(SI)与第二代FDA清除的多变量生物标志物检测(MIA2G)联合预测卵巢癌的性能。阳性SI或MIA2G正确识别96.1%的上皮性卵巢癌/输卵管癌(EOC/FTC)患者,SI与MIA2G评分均与恶性肿瘤风险(ROM)显著相关(p<0.001)。在患病率设为5%的模拟中,SI阴性且MIA2G评分为6者ROM为1.8%,而同MIA2G评分但SI阳性者ROM为10.5%,风险近6倍。

要点

  • 阳性SI或MIA2G正确识别96.1%的EOC/FTC患者。
  • SI与MIA2G评分均与ROM显著相关(p<0.001)。
  • 患病率5%模拟中,SI阴性且MIA2G评分6者ROM为1.8%,SI阳性者ROM为10.5%。

核心结论

  • 患者报告的症状指数与 refined 生物标志物 panel 联合可提高附件包块患者卵巢癌评估的准确性。
  • 该策略可为附件包块患者的恶性肿瘤风险提供个性化评估,以分诊至适当诊疗。

研究设计与样本

  • 前瞻性研究,纳入在三级医疗中心就诊的218例因附件包块拟手术患者。
  • 患者签署知情同意后完成症状指数(SI),并采集术前血清检测CA 125及第二代FDA清除的生物标志物检测(MIA2G)。
  • SI与MIA2G结果与手术所见及外科病理进行关联,采用逻辑回归模型评估SI与MIA2G的交互作用以确定恶性肿瘤风险(ROM)。

主要发现

  • 218例入组患者平均年龄53.6岁(范围18-86),147例(67.4%)为绝经后。
  • 64例(29.4%)为上皮性卵巢癌或输卵管癌(EOC/FTC),17例(7.8%)为交界性卵巢肿瘤。
  • 阳性SI或MIA2G正确识别96.1%的EOC/FTC患者。
  • 逻辑回归显示SI与MIA2G评分均与ROM显著相关(p<0.001)。
  • 在疾病患病率设为5%的模拟中,SI阴性且MIA2G评分为6的患者ROM为1.8%,而同MIA2G评分但SI阳性的患者ROM为10.5%,风险近6倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the performance of a symptom index (SI) and multivariate biomarker panel in the identification of ovarian cancer in women presenting for surgery with an adnexal mass. STUDY DESIGN: Prospective study of patients seen at a tertiary medical center. Following consent, patients completed an SI and preoperative serum was collected for individual markers (CA 125) and a second-generation FDA-cleared biomarker test (MIA2G). Results for the SI and MIA2G were correlated with operative findings and surgical pathology. Logistic regression modeling was performed to assess the interaction of the SI with MIA2G to determine the risk of malignancy (ROM). RESULTS: Of the 218 patients enrolled, the mean age was 53.6 years (range 18-86). One-hundred and forty-seven patients (67.4%) were postmenopausal. Sixty-four patients (29.4%) had epithelial ovarian cancer or fallopian tube cancer (EOC/FTC) and 17 (7.8%) had borderline ovarian tumors. A positive SI or MIA2G correctly identified 96.1% of patients with EOC/FTC. Using logistic regression, we found that both SI and MIA2G score were significantly associated with ROM (p < 0.001). In a simulation with disease prevalence set at 5%, patients with a negative SI and a MIA2G score of 6 had a ROM of 1.8% whereas patients with the same MIA2G and positive SI had a 10.5% ROM, nearly a 6-fold higher risk. CONCLUSIONS: The combination of a patient-reported symptom index and refined biomarker panel allows for improved accuracy in the assessment for ovarian cancer in patients with an adnexal mass. This strategy could offer a personalized approach to addressing ROM to triage patients with an adnexal mass to appropriate care.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Urban RR, Pappas TC, Bullock RG, et al. Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass. Gynecol Oncol. 2018. PMID: 29929922. doi:10.1016/j.ygyno.2018.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。